Evidence map›Paper›PMID 35877265›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.

Zainul-Abedin Kapacee, Jennifer Allison, Mohammed Dawod, Xin Wang, Melissa Frizziero, Bipasha Chakrabarty, Prakash Manoharan, Catherine McBain, Was Mansoor, Angela Lamarca and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Zainul-Abedin KapaceeDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Jennifer AllisonDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Mohammed DawodDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Xin WangStatistics Group, Digital Services, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.ORCID 0000-0001-5192-8093
Melissa FrizzieroCancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, UK.
Bipasha ChakrabartyDepartment of Pathology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Prakash ManoharanDepartment of Nuclear Medicine/Radiology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Catherine McBainDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Was MansoorDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Angela LamarcaDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Richard HubnerDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Juan W ValleDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.ORCID 0000-0002-1999-0863
Mairéad G McNamaraDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.ORCID 0000-0002-2272-3678
The Christie NHS Foundation Trust · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain metastases (BMs) in patients with extra-pulmonary neuroendocrine neoplasms (EP-NENs) are rare, and limited clinical information is available. The aim of this study was to detail the clinicopathological features, management and outcomes in patients with EP-NENs who developed BMs.

methodsA retrospective single-centre analysis of consecutive patients with EP-NENs (August 2004-February 2020) was conducted. Median overall survival (OS)/survival from BMs diagnosis was estimated (Kaplan-Meier).

resultsOf 730 patients, 17 (1.9%) had BMs, median age 61 years (range 15-77); 8 (53%) male, unknown primary NEN site: 40%. Patients with BMs had grade 3 (G3) EP-NENs 11 (73%), G2: 3 (20%), G1: 1 (7%). Eight (53%) had poorly differentiated NENs, 6 were well-differentiated and 1 was not recorded. Additionally, 2 (13%) patients had synchronous BMs at diagnosis, whilst 13 (87%) developed BMs metachronously. The relative risk of developing BMs was 7.48 in patients with G3 disease vs. G1 + G2 disease (

conclusionBMs in patients with EP-NENs are rare and of increased risk in G3 vs. G1 + G2 EP-NENs. Survival outcomes are poor, and a greater understanding is needed to improve therapeutic outcomes.

Indexed as

Brain NeoplasmsCarcinoma, NeuroendocrineNeuroendocrine TumorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesYoung Adultbrain metastasesextra pulmonary neuroendocrine neoplasmsneuroendocrine carcinoma

Identifiers

PMID35877265
PMCPMC9319979
OpenAlexW4286005613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.